NKARTA INC (NKTX)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for NKTX
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| NKTX | Chief Medical Officer and Head of Research and Development | ["Formerly served as President and Owner of an independent research and development advisory LLC","Chief Development Officer, Immunology at Vividion Therapeutics","Senior Vice President and Head of the Clinical Development Organization at Magenta Therapeutics","Led autoimmunity clinical development at Annexon Biosciences","Held positions of increasing responsibility at Johnson & Johnson","Director within Immunoscience at Bristol-Myers Squibb","Attending physician and researcher at the NIH Clinical Center","Completed internal medicine residency and clinical and research fellowship in Rheumatology"] | [] | 2026 |
Biography sourced from the proxy statement filing.
Shawn Rose, M.D., Ph.D. has served as our Chief Medical Officer and Head of Research and Development since June 2025. Dr. Rose formerly served as President and Owner of an independent research and development advisory LLC from April 2024 to June 2025. Prior to that, Dr. Rose served as Chief Development Officer, Immunology at Vividion Therapeutics from August 2023 to April 2024. Previously, he served as Senior Vice President and Head of the Clinical Development Organization at Magenta Therapeutics from February 2022 to February 2023, and led autoimmunity clinical development at Annexon Biosciences from October 2020 to February 2022. Dr. Rose previously held positions of increasing responsibility at Johnson & Johnson from April 2017 to October 2020, serving as Senior Director of Immunology Translational Science and Medicine and disease area strategic leader for rheumatology and autoimmunity. Prior to joining Johnson & Johnson, Dr. Rose was a director within Immunoscience at Bristol-Myers Squibb from August 2014 to April 2017. Dr. Rose began his career as an attending physician and researcher at the NIH Clinical Center from October 2012 to August 2014. Dr. Rose currently serves on multiple scientific advisory boards. Dr. Rose completed his internal medicine residency and clinical and research fellowship in the Rheumatology Division at Northwestern University. Dr. Rose holds an M.D. from the University of Miami Miller School of Medicine, a Ph.D. in Immunology from the University of Miami, and a B.S. in Psychobiology from the University of Miami.